Literature DB >> 32015164

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy.

Thomas A Hope1,2, Lisa Bodei3, Jennifer A Chan4, Ghassan El-Haddad5, Nicholas Fidelman6, Pamela L Kunz7, Josh Mailman8, Yusuf Menda9, David C Metz10, Erik S Mittra11, Daniel A Pryma12, Diane L Reidy-Lagunes13, Simron Singh14, Jonathan R Strosberg15.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32015164      PMCID： PMC9364765          DOI： 10.2967/jnumed.119.240911

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   11.082


× No keyword cloud information.
  57 in total

1.  Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.

Authors:  Ingo Janssen; Elise M Blanchet; Karen Adams; Clara C Chen; Corina M Millo; Peter Herscovitch; David Taieb; Electron Kebebew; Hendrik Lehnert; Antonio T Fojo; Karel Pacak
Journal:  Clin Cancer Res       Date:  2015-04-14       Impact factor: 12.531

2.  Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.

Authors:  Jingjing Zhang; Harshad R Kulkarni; Aviral Singh; Karin Niepsch; Dirk Müller; Richard P Baum
Journal:  J Nucl Med       Date:  2018-08-16       Impact factor: 10.057

3.  Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.

Authors:  Ebrahim S Delpassand; Amin Samarghandi; Sara Zamanian; Edward M Wolin; Mohammadali Hamiditabar; Gregory D Espenan; Jack L Erion; Thomas M O'Dorisio; Larry K Kvols; Jaime Simon; Robert Wolfangel; Arthur Camp; Eric P Krenning; Alireza Mojtahedi
Journal:  Pancreas       Date:  2014-05       Impact factor: 3.327

4.  Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.

Authors:  Samer Ezziddin; Feras Khalaf; Maria Vanezi; Torjan Haslerud; Karin Mayer; Abdullah Al Zreiqat; Winfried Willinek; Hans-Jürgen Biersack; Amir Sabet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-07       Impact factor: 9.236

5.  Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.

Authors:  Maddalena Sansovini; Stefano Severi; Annarita Ianniello; Silvia Nicolini; Lorenzo Fantini; Emilio Mezzenga; Fabio Ferroni; Emanuela Scarpi; Manuela Monti; Alberto Bongiovanni; Sara Cingarlini; Chiara Maria Grana; Lisa Bodei; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-04       Impact factor: 9.236

6.  Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy.

Authors:  Samer Ezziddin; Martin Opitz; Mared Attassi; Kim Biermann; Amir Sabet; Stefan Guhlke; Holger Brockmann; Winfried Willinek; Eva Wardelmann; Hans-Jürgen Biersack; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-18       Impact factor: 9.236

Review 7.  The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.

Authors:  Jonathan R Strosberg; Thorvardur R Halfdanarson; Andrew M Bellizzi; Jennifer A Chan; Joseph S Dillon; Anthony P Heaney; Pamela L Kunz; Thomas M O'Dorisio; Riad Salem; Eva Segelov; James R Howe; Rodney F Pommier; Kari Brendtro; Mohammad A Bashir; Simron Singh; Michael C Soulen; Laura Tang; Jerome S Zacks; James C Yao; Emily K Bergsland
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

8.  Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.

Authors:  Emilio Bertani; Nicola Fazio; Davide Radice; Claudio Zardini; Chiara Grana; Lisa Bodei; Luigi Funicelli; Carlo Ferrari; Francesca Spada; Stefano Partelli; Massimo Falconi
Journal:  Ann Surg Oncol       Date:  2016-09-09       Impact factor: 5.344

9.  Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index.

Authors:  Silvia Nicolini; Stefano Severi; Annarita Ianniello; Maddalena Sansovini; Alice Ambrosetti; Alberto Bongiovanni; Emanuela Scarpi; Francesca Di Mauro; Alice Rossi; Federica Matteucci; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-01       Impact factor: 9.236

10.  Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.

Authors:  W A van der Zwan; T Brabander; B L R Kam; J J M Teunissen; R A Feelders; J Hofland; E P Krenning; W W de Herder
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-28       Impact factor: 9.236
View more
  17 in total

1.  Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Curr Probl Surg       Date:  2020-05-15       Impact factor: 1.909

2.  Neuroendocrine hepatic metastatic disease: the surgeon's perspective.

Authors:  Seth J Concors; Jessica E Maxwell
Journal:  Abdom Radiol (NY)       Date:  2022-04-27

Review 3.  Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues.

Authors:  Parul Agarwal; Amr Mohamed
Journal:  Curr Treat Options Oncol       Date:  2022-08-08

Review 4.  Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

Authors:  Thomas A Hope; Marianne Pavel; Emily K Bergsland
Journal:  J Clin Oncol       Date:  2022-06-01       Impact factor: 50.717

5.  Highly variable biodistribution of 68Ga labeled somatostatin analogues 68Ga-DOTA-NOC and 68Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT.

Authors:  Monica Cheng; Mark Tann
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

6.  A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy.

Authors:  Satya Das; Liping Du; Aimee Schad; Shikha Jain; Aaron Jessop; Chirayu Shah; David Eisner; Dana Cardin; Kristen Ciombor; Laura Goff; Marques Bradshaw; Dominique Delbeke; Martin Sandler; Jordan Berlin
Journal:  Endocr Relat Cancer       Date:  2021-03       Impact factor: 5.678

Review 7.  Somatostatin receptor radionuclide therapy in neuroendocrine tumors.

Authors:  Mintallah Haider; Satya Das; Taymeyah Al-Toubah; Eleonora Pelle; Ghassan El-Haddad; Jonathan Strosberg
Journal:  Endocr Relat Cancer       Date:  2021-03       Impact factor: 5.678

Review 8.  The Landmark Series: Management of Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Ann Surg Oncol       Date:  2021-01-15       Impact factor: 5.344

9.  Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors.

Authors:  Elena María Vida Navas; Alberto Martínez Lorca; Aintzane Sancho Gutiérrez; Lucia Sanz Gómez; Teresa Navarro Martínez; Enrique Grande Pulido; Alfredo Carrato Mena; Pablo Gajate Borau
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-15       Impact factor: 5.555

Review 10.  Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.

Authors:  Maria I Del Olmo-García; Stefan Prado-Wohlwend; Pilar Bello; Angel Segura; Juan F Merino-Torres
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.